Microsoft Faces Lawsuit Claiming Up to $2.8B
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy MSFT?
Microsoft (MSFT) will have to face a mass lawsuit alleging it overcharged thousands of British businesses to use its Window Server software on services provided by Amazon (AMZN), Google (GOOGL), and Alibaba (BABA), Reuters reports. Competition lawyer Maria Luisa Stasi is bringing the case on behalf of 60,000 businesses and her lawyers have said the claim was worth up to $2.8B.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MSFT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MSFT
Wall Street analysts forecast MSFT stock price to rise
34 Analyst Rating
32 Buy
2 Hold
0 Sell
Strong Buy
Current: 432.920
Low
500.00
Averages
631.36
High
678.00
Current: 432.920
Low
500.00
Averages
631.36
High
678.00
About MSFT
Microsoft Corporation is a technology company. The Company develops and supports software, services, devices, and solutions. The Company’s segments include Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment consists of products and services in its portfolio of productivity, communication, and information services. This segment primarily comprises: Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of server products and cloud services, including Azure and other cloud services, SQL Server, Windows Server, Visual Studio, System Center, and related Client Access Licenses (CALs), and Nuance and GitHub; and Enterprise Services, including enterprise support services, industry solutions and Nuance professional services. The More Personal Computing segment primarily comprises Windows, Devices, Gaming, and search and news advertising.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Acquisition Interest: Microsoft recently considered acquiring AI coding startup Cursor for $60 billion but ultimately did not make an offer, indicating competitive pressure in the rapidly evolving AI tools market.
- Market Competition: Despite GitHub Copilot gaining 4.7 million paying subscribers, a 75% increase year-over-year, Cursor and its rivals Anthropic and OpenAI continue to dominate the market, highlighting Microsoft's insufficient investment in the AI sector.
- SpaceX Acquisition: SpaceX announced it has secured the right to acquire Cursor for $60 billion, with a $10 billion penalty if the deal does not close, reflecting Elon Musk's strong interest and investment intentions in the AI space.
- Financing Dynamics: Cursor was valued at $50 billion during its fundraising process, underscoring the strong demand for tools that facilitate rapid website and application development, while also indicating ongoing investor interest in the AI sector.
See More
- FDA Rejection: AbbVie's anti-wrinkle therapy TrenibotE was not approved by the FDA, resulting in a 0.40% drop in its stock price, highlighting regulatory challenges that may impact future revenue growth in the biopharmaceutical sector.
- Strong Earnings Boost: Procter & Gamble's FQ3 earnings report revealed a 3% organic sales increase, surpassing the 2.8% market expectation, leading to a 3.4% rise in stock price, indicating broad-based growth across product categories and regions that enhances market confidence.
- Weight Loss Script Decline: Eli Lilly's weight loss drug Zepbound saw a ~2% drop in weekly prescriptions, while competitor Novo Nordisk's Wegovy prescriptions rose by 7%, causing Eli Lilly's stock to fall by 1.84%, reflecting the intense competition in the obesity treatment market.
- Microsoft's Buyout Offer: Microsoft offered voluntary buyouts to about 7% of its U.S. workforce, resulting in a 1.11% stock price increase, marking a strategic shift in response to the rise of artificial intelligence, which may affect its future human resource allocation.
See More
- Market Sentiment: European stocks are poised for a downbeat end to the week amid ongoing concerns about the U.S.-Iran ceasefire, reflecting investor sensitivity to geopolitical risks.
- Tech Stock Rebound: Despite a negative session for Wall Street, U.S. futures were tentatively higher on Friday, with a rebound in tech stocks boosting the Nasdaq in premarket trading, indicating sustained confidence in the tech sector.
- Investment Strategy Advice: Kenny Polcari of SlateStone Wealth advises clients to remain calm amid market volatility, suggesting they buy the dip and focus on core AI stocks like IBM, Microsoft, and Nvidia for potential future gains.
- Commodity Investment Opportunities: Dominic Schnider from UBS Wealth Management emphasizes that increasing exposure to commodities can significantly reduce volatility, recommending diversified investments in energy, metals, and agriculture to navigate stock market uncertainties.
See More
- Deal Details: Meta has entered into a deal with Amazon to utilize hundreds of thousands of Graviton AI chips for at least three years, demonstrating the company's commitment to investing in infrastructure to meet high computing demands.
- Market Demand and Layoffs: Despite announcing layoffs of around 8,000 employees, or 10% of its workforce, Meta's partnership with Amazon indicates ongoing investment in infrastructure to address the increasing user demand across its platforms.
- Technical Advantages: Graviton chips can handle a wide range of computing tasks, particularly suited for AI workloads, with Amazon claiming they offer the best performance-to-price ratio in its EC2 service while using 60% less energy, enhancing Meta's operational efficiency.
- Industry Trends: Meta's choice reflects a resurgence of CPU importance in the AI era, as demand for high-performance computing rises, with Graviton adoption positioning Meta as one of the top five customers, further solidifying its competitive stance in the AI sector.
See More
- Massive Investment: Amazon's $20 billion investment in AI-driven data centers in Pennsylvania is causing political turmoil in key districts, potentially impacting control of the U.S. House.
- Intense District Competition: The four congressional districts in eastern Pennsylvania are considered swing areas, where Democratic Governor Josh Shapiro's expansion plans may pressure incumbent Republicans, especially ahead of the upcoming elections.
- Growing Public Opposition: The opposition to data center construction is intensifying, particularly in the Lehigh Valley, where residents express concerns about rising electricity costs and environmental impacts, forming a bipartisan coalition against the projects.
- Election Impact from Rising Costs: Pennsylvania's electricity rates surged by 21.7% in 2025, and the associated costs linked to data centers could burden Republican incumbents in elections, forcing them to navigate between supporting data centers and addressing constituents' concerns.
See More
- Tech Stock Plunge: ServiceNow's stock plummeted over 17%, marking its worst single-day drop ever, as the company acknowledged business pressures from the Middle East conflict, contributing to the Nasdaq's worst performance since March, with investors concerned about AI threats to software firms.
- Oil Price Decline: Crude oil prices fell amid reports of Iranian negotiators heading to Pakistan, boosting market hopes for a resumption of U.S.-Iran peace talks, while an extended ceasefire between Israel and Lebanon also added to traders' optimism.
- Layoff Surge: Microsoft announced voluntary buyouts for about 7% of its U.S. workforce, while Meta plans to cut around 8,000 jobs, and Nike is eliminating 1,400 positions in its second round of layoffs this year, highlighting increasing pressures in the tech sector.
- Drug Price Agreements: Regeneron announced it will lower drug prices through deals with the White House and provide the first hearing-loss gene therapy for free to eligible U.S. patients, joining a growing number of pharmaceutical companies seeking exemptions from steep tariffs in exchange for price reductions.
See More










